Drugs / AB-1002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04179643 | Nov 2019 → Aug 2024 overdue | cardiac rhythm disease, diastolic heart failure, ischemic disease, systolic heart failure | AskBio Inc | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05598333 | Oct 2023 → Oct 2026 expected | congestive heart failure | AskBio Inc | Active not recruiting | No outcome recorded |
Press releases naming this drug 12 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04179643 ↗ |
| Action | Inhibit | “delivers constitutively active protein phosphatase 1 inhibitor 1 to cardiomyocytes” PMID 41120766 ↗ Oct 2025 |
| Modality | Gene therapy (AAV / viral vector) | “a chimeric cardiotropic adeno-associated viral vector” PMID 41120766 ↗ Oct 2025 |
| Route | Other | “single intracoronary infusion of AB-1002” NCT04179643 ↗ |